Curcumin-loaded PLGA Nanoparticles Conjugated with Anti-P-glycoprotein Antibody to Overcome Multidrug Resistance

Punfa, Wanisa; Suzuki, Shugo; Pitchakarn, Pornsiri; Yodkeeree, Supachai; Naiki, Taku; Takahashi, Satoru; Limtrakul, Pornngarm

doi:10.7314/apjcp.2014.15.21.9249

Cited by 31 publications

(25 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mobile phase comprised 52% acetonitrile and 48% citric buffer (1% w/v citric acid, pH 3.0) and flow rate was set at 1 mL/min. Detection wavelengths for curcumin and analog 2A were 425 and 340 nm, respectively . Concentration of curcumin or analog 2A in serum was calculated and compared to standard curve (0‐3200 ng/mL).…”

Section: Methodsmentioning

confidence: 99%

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

et al. 2018

Self Cite

View full text Add to dashboard Cite

Many prostate cancer patients develop resistance to treatment called castration‐resistant prostate cancer (CRPC) which is the major cause of recurrence and death. In the present study, four cyclohexanone curcumin analogs were synthesized. Additionally, their anticancer progression activity on CRPC cell lines, PC3 and PLS10 cells, was examined. We first determined their anti‐metastasis properties and found that 2,6‐bis‐(4‐hydroxy‐3‐methoxy‐benzylidene)‐cyclohexanone (2A) and 2,6‐bis‐(3,4‐dihydroxy‐benzylidene)‐cyclohexanone (2F) showed higher anti‐invasion properties against CRPC cells than curcumin. Analog 2A inhibited both MMP‐2 and MMP‐9 secretions and activities, whereas analog 2F reduced only MMP activities. These findings suggest that the compounds may inhibit CRPC cell metastasis by decreased extracellular matrix degradation. Analog 2A, the most potent analog, was then subjected to an in vivo study. Similar to curcumin, analog 2A was detectable in the serum of mice at 30 and 60 minutes after i.p. injections. Analog 2A and curcumin (30 mg/kg bodyweight) showed a similar ability to reduce tumor area in lungs of mice that were i.v. injected with PLS10 cells. Additionally, analog 2A showed superior growth inhibitory effect on PLS10 cells than that of curcumin both in vitro and in vivo. The compound inhibited PLS10 cells growth by induction of G1 phase arrest and apoptosis in vitro. Interestingly, analog 2A significantly decreased tumor growth with downregulation of cell proliferation and angiogenesis in PLS10‐bearing mice. Taken together, we could summarize that analog 2A showed promising activities in inhibiting CRPC progression both in vitro and in vivo.

show abstract

Section: Methodsmentioning

confidence: 99%

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Antiproliferative studies and downregulation of clonogenic potential of HeLa cells proved the better antitumor activity of PLGA NanoCur [87]. Similarly, Punfa et al [156] demonstrated the enhanced uptake and anticancer activity of CURloaded PLGA NPs in drug resistant cancer cells by conjugation with anti-Pgp [88,156]. The specific binding of CUR-NPs-APgp to KB-V1 cells was significantly higher than that to KB-3-1 cells.…”

Section: Polymeric Npsmentioning

confidence: 90%

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

Ahmad

Alkahtani

Akhter

et al. 2015

Journal of Drug Targeting

View full text Add to dashboard Cite

Comprehensive pharmacological screening of curcumin (CUR) has given the evidence that it is an excellent naturally occurring therapeutic moiety for cancer. It is very well tolerated with insignificant toxicity even after high doses of oral administration. Irrespective of its better quality as an anticancer agent, therapeutic application of CUR is hampered by its extremely low-aqueous solubility and poor bioavailability, rapid clearance and low-cellular uptake. A simple means of breaking up the restrictive factor of CUR is to perk-up its aqueous solubility, improve its bioavailability, protect it from degradation, and metabolism and potentiate its targeting capacity towards the cancer cell. The development in the field of nanomedicine has made excellent progresses toward enhancing the bioavailability of lipophilic drugs like CUR. Nanoparticles (NPs) are capable to deliver the CUR at specific area and thereby prevent it from physiological degradation and systemic clearance. In recent year, an assortment of nanomedicine-based novel drug delivery system has been designed to potentiate the bioavailability of CUR towards anticancer therapy. In this review, we discuss the recent development in the field of nanoCUR (NanoCur), including polymeric micelles, liposome, polymeric NPs, nanoemulsion, nanosuspension, solid lipid NPs (SLNPs), polymer conjugates, nanogel, etc. in anticancer application.

show abstract

“…Moreover, polylactic-co-glycolic acid nanoparticles containing curcumin were described in another study as having a higher cellular uptake and cytotoxic effect in cervical cancer cells, when compared to curcumin alone [50]. Furthermore, in a subsequent study, these authors conjugated the same nanoparticles (loaded with curcumin) with an anti-P-gp antibody in order to obtain a more targeted therapy [51]. These new nanoparticles presented a more pronounced cytotoxic effect against an MDR cervical cancer model than the nanoparticles without the P-gp antibody [51].…”

Section: Strategies For Overcoming the Limitations Of Curcuminmentioning

confidence: 99%

“…Furthermore, in a subsequent study, these authors conjugated the same nanoparticles (loaded with curcumin) with an anti-P-gp antibody in order to obtain a more targeted therapy [51]. These new nanoparticles presented a more pronounced cytotoxic effect against an MDR cervical cancer model than the nanoparticles without the P-gp antibody [51]. …”

Section: Strategies For Overcoming the Limitations Of Curcuminmentioning

confidence: 99%

Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives

2016

View full text Add to dashboard Cite

Multidrug resistance (MDR) presents a serious challenge to the efficiency of cancer treatment, and may be associated with the overexpression of drug efflux pumps. P-glycoprotein (P-gp) is a drug efflux pump often found overexpressed in cases of acquired MDR. Nevertheless, there are no P-gp inhibitors being used in the current clinical practice, due to toxicity problems, drug interactions, or pharmacokinetic issues. Therefore, it is important to identify novel inhibitors of P-gp activity or expression. Curcumin is a secondary metabolite isolated from the turmeric of Curcuma longa L. which has been associated with several biological activities, particularly P-gp modulatory activity (by inhibiting both P-gp function and expression). However, curcumin shows extensive metabolism and instability, which has justified the recent and intensive search for analogs of curcumin that maintain the P-gp modulatory activity but have enhanced stability. This review summarizes and compares the effects of curcumin and several curcumin analogs on P-glycoprotein function and expression, emphasizing the potential of these molecules for the possible development of safe and effective inhibitors of P-gp to overcome MDR in human cancer.

show abstract

Curcumin-loaded PLGA Nanoparticles Conjugated with Anti-P-glycoprotein Antibody to Overcome Multidrug Resistance

Cited by 31 publications

References 36 publications

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

Cyclohexanone curcumin analogs inhibit the progression of castration‐resistant prostate cancer in vitro and in vivo

Progress in nanotechnology-based drug carrier in designing of curcumin nanomedicines for cancer therapy: current state-of-the-art

Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives

Contact Info

Product

Resources

About